Blog

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale–29

Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale–29

There is increasing emphasis on using patient-reported outcomes (PROs) to complement traditional clinical outcomes in medical research, including in multiple sclerosis (MS). Research, particularly in oncology and heart failure, has shown that PROs can be prognostic of hard clinical endpoints such as survival time (time from study entry until death). However, unlike in oncology or cardiology, it is unknown whether PROs are associated with survival time in neurological diseases. The Multiple Sclerosis Impact Scale–29 (MSIS-29) is a PRO sensitive to short-term change in MS, with questions covering both physical and psychological quality of life. This study aimed to investigate whether MSIS-29 scores can be prognostic for survival time in MS, using a large observational cohort of people with MS.

Read More
Patients With Advanced Cancer Live Longer When They Report Symptoms Online and in Real Time

Patients With Advanced Cancer Live Longer When They Report Symptoms Online and in Real Time

Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring, according to findings of a randomized trial reported at the 2017 ASCO Annual Meeting and published simultaneously online in JAMA.

Read More
Patient-reported outcomes poised to improve cancer care

Patient-reported outcomes poised to improve cancer care

Patient-reported outcomes (PROs) are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development—and even routine clinical cancer care, according to experts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, held June 3–7 in Chicago.

Read More
The Rise of Patient-Reported Outcomes in Oncology

The Rise of Patient-Reported Outcomes in Oncology

Just a few years ago, few had heard of the term “patient-reported outcome” or “PRO.” Now, PROs seem to come up frequently in discussions about almost every aspect of oncology—in clinical care delivery, clinical trials, quality assessment, and comparative effectiveness research (Fig. 1 shows uses and benefits of PROs in each of these contexts).

Read More
Better patient-reported outcome scores seen for primary vs revision hip arthroscopy

Better patient-reported outcome scores seen for primary vs revision hip arthroscopy

BOSTON — Patients who underwent primary hip arthroscopy experienced greater improvement in patient-reported outcome scores at 2-year follow-up compared with patients who underwent revision arthroscopy, according to results presented at the Arthroscopy Association of North America Annual Meeting.

Read More
Integrating patients’ views in clinical studies of anticancer medicines

Integrating patients’ views in clinical studies of anticancer medicines

The European Medicines Agency (EMA) has published new guidance on the use of patient-reported outcome (PRO) measures in oncology studies. The new guidance is an appendix to the guideline on the evaluation of anticancer medicinal products in man, which was last revised in July 2013.

Read More